A Mini-Review of the NADPH Oxidases in Vascular Dementia: Correlation with NOXs and Risk Factors for VaD

Dong-Hee Choi 1,2 and Jongmin Lee 2,3,*

1 Center for Neuroscience Research, Institute of Biomedical Science & Technology, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 143701, Korea; dchoi@kku.ac.kr
2 Department of Medical Science, Konkuk University School of Medicine, 120 Neungdong-ro, Gwangjin-gu, Seoul 143701, Korea
3 Department of Rehabilitation Medicine, Konkuk University School of Medicine, 120 Neungdong-ro, Gwangjin-gu, Seoul 143701, Korea
* Correspondence: leej@kuh.ac.kr; Tel.: +82-22030-5345; Fax: +82-2030-7899

Received: 30 September 2017; Accepted: 21 November 2017; Published: 22 November 2017

Abstract: Oxidative stress (OS) is one of the factors that cause dementia conditions such as Alzheimer’s disease and vascular dementia (VaD). In the pathogenesis of VaD, OS is associated with risk factors that include increased age, hypertension, and stroke. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOXs) are a molecular source of reactive oxygen species (ROS). According to recent studies, inhibition of NOX activity can reduce cognitive impairment in animal models of VaD. In this article, we review the evidence linking cognitive impairment with NOX-dependent OS, including the vascular NOX and non-vascular NOX systems, in VaD.

Keywords: oxidative stress (OS); vascular dementia (VaD); reactive oxygen species (ROS); NADPH oxidases (NOX); cognitive impairment; risk factors

1. Introduction

Vascular dementia (VaD) is the second most frequent type of dementia and accounts for 17% to 25% of all cases of dementia worldwide [1–3]. It is recognized by the common symptoms of cognitive function decline including reasoning, executive functions, memory, language, perception, and knowledge and cerebrovascular pathologies [4–6]. Although the exact etiopathogenesis of VaD remains unknown, the evidence reported to date seems to indicate that it has multiple causes including cerebrovascular disease and coexisting vascular risk factors such as aging, hypertension, atherosclerosis, and stroke [7–10]. Growing evidence indicates that atherosclerotic pathologies of the vasculature are a hallmark of the development of VaD [4], and that oxidative stress (OS) plays a causative role in atherosclerosis and other cardiovascular diseases [11]. Many of the risk factors of cerebrovascular disease and VaD also involve elevated OS [12].

OS imbalances the ratio of antioxidants and reactive oxygen species (ROS) resulting in damage to vessel endothelia, glial and neuronal cells, leading to neurovascular uncoupling and further cerebral blood flow reduction [6,13]. The overproduced ROS can destroy mitochondrial function and further induce hypoxia and OS [6,14]. The brain has multiple sources of ROS; however, it has been shown that membrane-bound nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) enzymes are the primary sources of ROS during aging, hypoperfusion, stroke and hypertension [15]. ROS produced by NOX, which represent a major ROS-generation system, are often associated with the increased OS observed in the VaD and its risk factors [16,17]. Figure 1 shows the risk factors and NOXs of the ROS dependent mechanism for VaD.
Recent experimental studies have demonstrated that the inhibition of NOX activity attenuated chronic cerebral hypoperfusion-induced cognitive impairment in a rodent model [18,19]. In this review, we examined the current state of research regarding the roles of NOX in cognitive decline in VaD. In addition to NOX in VaD, we discussed the link between NOX and cognitive impairment in non-vascular cognitive disorders. To determine the association of NOX in cognitive impairment a keyword search on PubMed using the terms “cognitive impairment NADPH oxidase” yielded 76 citations, regardless of the year of publication. Search details of “cognitive impairment NADPH oxidase” was “cognitive dysfunction” or “cognitive” and “dysfunction” or “cognitive dysfunction” or “cognitive” and “impairment” or “cognitive impairment” and “NADPH oxidase” or “NADPH” and “oxidase” or “NADPH oxidase”. We excluded 16 review articles, two articles for cell studies, 11 articles included indirect correlation with NOX and cognitive function, and 12 articles with unmeasured cognitive function. We searched the reference lists of articles identified by this search strategy and selected those we judged relevant. Thirty-five publications were selected for this research.

2. Association between Vascular Dementia (VaD) and Risk Factors and Oxidative Stress (OS)

In general, the risk factors for VaD are similar to those reported for cardiovascular disease and stroke. The risk factors for the development of dementia after stroke are multifactorial and contain age rising, vascular risk factors, stroke region, stroke incidence, global brain atrophy, and medical temporal lobe atrophy [20–22]. Comparable risk factors have been determined for VaD without stroke incidence, most notably increasing age and vascular risks, such as high cholesterol, hypertension, and atherosclerosis [20,23].

OS is caused by an environment where imbalance between the production of ROS and removal of ROS by antioxidant species is linked to the pathogenesis of dementia [24]. An enhanced level of ROS in the vasculature, suppressed nitric oxide bioactivities, and abnormal endothelial function resulting to vascular disease, are associated with VaD [24]. Although studies measuring markers of OS specifically in VaD are limited, there are data supporting a role for OS in this form of dementia, with most studies performed to date investigating markers of OS in the circulation [24]. Those studies reported a reduction in plasma antioxidant levels [25], elevation of plasma lipid peroxidation [26,27], and increased DNA oxidation in the cerebrospinal fluid [28] of patients with VaD. Regarding OS, it is linked to its risk factors as well as to VaD. Several reports have demonstrated that OS is involved in the pathogenesis of diabetes [29] and hypercholesterolemia [30]. Moreover, it has been reported that
mitochondrial-induced OS is involved in hypertension-related vasculature damage [31], and that OS is responsible for the oxidation of low-density lipoproteins in atherosclerosis [32,33] and for the high levels of lipid hydroperoxides observed after ischemic stroke [16,34].

3. NADPH Oxidase in Cerebrovascular Disease

3.1. NADPH Oxidase—An Overview

The family of NAPDH oxidases (NOXs) enzymes is a major source of ROS generation in various tissues [18]. These enzymes are capable of transporting electrons across the plasma membrane and producing superoxide [35]. The phagocytic NOX oxidase (gp91phox or NOX2) was the first identified in phagocytes [36] and is in charge of host defense via the release of considerable amounts of superoxide into phagosomes [18]. Seven NOX isoforms consisting of NOX1, NOX2, NOX3, NOX4, NOX5, dual oxidase (DUOX)1, and DUOX2, have been expressed in a variety of tissues, including brain [18,37].

The NOX and DUOX isoforms have similar binding sites for heme, flavin adenine dinucleotide, and NADPH [38,39] within each isoform and six conserved transmembrane α-helices [35]. Both DUOX 1 and DUOX2 contain an additional transmembrane α-helix, followed by a domain that is homologous to peroxidases [35]. The NOX and DUOX enzymes are differentially expressed and their regulation depends on the pathophysiological state of the body and brain [40].

NOX1 and NOX2 assemble with p22phox, and the full activation of p22phox with NOX1 and NOX2 need to bind with other regulatory subunits, p47phox (or its homolog NOX organizer 1, NOXO1), p67phox (or the homologous NOX activator 1, NOXA1), and Ras-related C3 botulinum toxin substrate (Rac) [41–44]. NOX4 has intrinsic activation and affinity with p22phox, but is not essential to other subunits for activation. NOX5 activation is regulated in a calcium–calmodulin-dependent manner, but not need any other subunit [41,43,44].

3.2. NOX-Dependent Generation of ROS Involves in Cerebrovascular Impairment

Recently, four isoforms (NOX1, 2, 4, and 5) of NADPH oxidases were discovered in vascular cells and have been shown to play a leading role in various physiological processes, including endothelial function, vascular tone, and vessel generation, as well as in vascular pathological conditions such as hypertension and stroke [45,46]. The activity of NOX in cerebral arteries is much higher than it is in the peripheral arteries [46]. Several studies have reported that NOX1, NOX2, and NOX4 manifested in cerebral arteries [47–50]. Kazama et al. reported that the NOX2 protein was expressed in endothelial and adventitial cells of cerebral resistance arteries [50]. Miller et al. found that the NOX4 protein was very highly (≥10-fold higher) expressed in rat basilar arteries when compared with the aorta, carotid, and mesenteric arteries [48]. Ago et al. [49] also showed that mRNA for NOX1, NOX2, and NOX4 were expressed in rat basilar endothelial and vascular smooth muscle (VSM) cells. The expression results, ranked in ascending order, are as follows: NOX2 < NOX1 < NOX4. They also demonstrated that the levels of mRNA or protein for NOX1 in endothelial cells were greater than in the VSM cells of basilar arteries [49]. The fine-tuned balance between the NOX-dependent generation of ROS and their detoxification by dismutase enzymes is a very delicate process [45].

The alteration of this balance in disease states result in either an over- or underproduction of ROS induced by vascular damage [45]. Several studies have highlighted the involvement of NOX isoforms in the pathophysiological process of vascular disease [51]. Increased expression of NOX subtypes is determined in various conditions including hypertension [47], insulin resistance [52], diabetes [53,54], and aging [55], ischemic stroke [56], and subarachnoid hemorrhage [57]. In particular, NOX1 and NOX2 have been shown to play deleterious roles [45], whereas NOX4 potentially plays a protective role in vascular diseases such as atherosclerosis [58]. Hence, increasing alteration of NOX expression arises in the status of pathophysiology. Subsequently enhancing of superoxide production would be expected through the increase of NOX activation in variety of disease [51].
4. NADPH Oxidase in Risk Factors for VaD

4.1. Increased NOX Expression is Associated with Increasing Age

Increased NOX activity is related to various cerebrovascular diseases and their risk factors. Cerebrovascular disease is thought to become more common with increasing age as older patients have an increased incidence of ischemic stroke and vascular cognitive impairment affects older persons [59,60]. Ali et al. have reported that the increased NOX-derived production of ROS induced learning and memory impairments observed in aged female rats [61]. Resting cerebral blood flow is reduced and cerebral circulation is dysregulated in older individuals [59,62]. These cerebrovascular effects are linked to the enhanced production of ROS in neuronal cells and cerebral vasculature [63]. Park et al. [64] reported that NOX-dependent ROS generated in neurons and blood vessels could involve the cerebrovascular disruption in older mice. Those ROS production and cerebrovascular dysfunction in the brain of 12-month-old mice were reversed by the NOX peptide inhibitor gp91ds-tat [64]. Moreover, the increase in ROS production was not determined in aged NOX2(-/-) mice [64]. Thus, NOX2(-/-) mice are reduced the oxidative stress and cerebrovascular damage induced by advancing age [64]. These findings suggested that NOX2 is a pivotal source of the neurovascular OS that induces the harmful cerebrovascular effects that are associated with increasing age [64].

4.2. NOX in Hypertension

The detailed role of vascular NOX oxidases as one of the first pathologies of hypertension has previously been elucidated [65]. Angiotensin II (Ang II) plays a central role via the renin–angiotensin system in the vascular transformation related to hypertension [46], and is an important inducer of increased NOX-dependent superoxide generation in the vascular smooth muscle cells [66] and throughout the cerebral vasculature [67–70]. Ang II induces vascular disease by various mechanisms that lead to ROS-mediated damage and endothelial dysfunction [71]. Ang II is functionally linked to NOX1, NOX2, and diverse to NOX4 in the vasculature [44]. The expression of the catalytic subunits of NOX1, NOX2, and NOX4 and of the p22phox cytosolic subunit are increased by Ang II stimulation [65,72,73]. Ang II-activated NOX1 and NOX2 appear to be important in vascular smooth muscle cells (VSMCs) from large and small arteries, respectively, in humans [44,74–76]. Nguyen Dinh Cat et al. demonstrated that NOX4 expression was higher in endothelial cells than in VSMCs, in basal conditions [44]. Activation of NOXs is mediated through the binding of Ang II to the Ang II-angiotensin receptor type 1 [77]. Ang II-mediated NOX activation sequentially produces intracellular H$_2$O$_2$, which induces vascular hypertrophy [78].

Recent studies have demonstrated that NOX activation participates in the pathogenesis of hypertension and associated vascular dysfunction [79]. NOX2-deficient(-/-) mice do not exhibit cerebrovascular OS and are spared from the alterations in cerebral blood vessels and functional hyperemia induced by Ang II [50,80,81]. Moreover, a peptide that inhibits the gathering of NOX oxidase or a pharmacological inhibitor of this enzyme suppresses the ROS generation and cerebrovascular dysfunction caused by Ang II [80–82]. The detrimental role of NOX1 and NOX2 in the vascular system has been verified in studies of gene-specific deletion or overexpression, whereas the functional importance of NOX4 remains controversial [79]. Schröder et al. have shown that endogenous NOX4 protected the vasculature during femoral artery ligated ischemic stress in animal models [79,83,84]. They found that NOX4-deficient animals had angiotensin II–induced hypertrophic and proinflammatory aortic response. Deletion of NOX4 increased inflammatory activation and aortic media hypertrophy in response to angiotensin II and reduced activation of endothelial nitric oxide synthase, nitric oxide production, and the heme oxygenase-1 (HO-1) system. In contrast, genetic deletion of NOX1 attenuated angiotensin II–induced vascular hypertrophy [79,83,84]. However, the protective role of NOX4 may differ from its role in the brain where NOX4 has been shown to contribute to OS and the neurodegeneration linked to stroke and other pathological conditions [79,85]. Therefore, further studies are required to determine the exact role of NOX4 in cerebrovascular diseases.
4.3. NOX in Stroke

There are three major types of stroke: ischemic stroke, subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH) (Table 1) [86]. Both the depletion of oxygen during ischemia and the replenishment of oxygen during reperfusion result in the tissue damage observed in stroke [40]. Ischemia/reperfusion injury is related to increased levels of ROS. OS can arise from increased generation of ROS in the ischemia/reperfusion injury [87,88]. There is increasing evidence that NOX-mediated ROS contribute to the pathology that follows cerebral ischemia/reperfusion [35,89–91]. Increased activation of the NOX1 [92], NOX2 [92–95], and NOX4 [85,96] isoforms is involved in ROS production and the development of the pathological condition that follows cerebral ischemia [40]. The expression of NOX1, NOX2, and NOX4 after focal cerebral ischemia was assessed in various cell types, including neurons, astrocytes, and microglia [40]. Remarkably, superoxide production and NOX2 expression have also been shown to be increased in mouse cerebral arteries after focal cerebral ischemia [95]. NOX-oxidase-mediated ROS and Rac1 activation in the hippocampus contributes to cognitive impairment after cerebral ischemia [97,98]. Recent studies have suggested that NOX activation is associated with hippocampal cell death and cognitive impairment in rats with cerebral hypoperfusion [18,19,99]. A recent study reported that the upregulation of p47phox oxidase induces spatial memory deficits and hippocampal oxidative DNA damage in chronic intermittent hypoxia conditions [100]. This finding suggests that these factors contribute considerably to cerebral ischemia-induced vascular dysfunction and are risk factors for VaD [40,95].

There are two types of hemorrhagic stroke: SAH and ICH. SAH is one of the most destructive cerebrovascular diseases [86]. Increased NOX activation has also been associated with the pathology of SAH [40]. Animal studies have reported that elevation of superoxide occurred as early as 12 h after SAH [57] followed by the enhancement of the expression and activation of NOX2 (gp91phox) [101–103], p47phox [104], and Rac1 [57] in the rat cortex or striatum at 12–48 h after SAH. The most recent study in this area demonstrated that the levels of the NOX2 and NOX4 proteins were increased in the perilesional neurons and astrocytes in brain tissues from patients with SAH. In an SAH rat model, the NOX2 inhibitor gp91ds-tat and the NOX4 inhibitor GKT137831 decreased SAH-induced neuronal death and degeneration [105].

In a rat model of the other type of hemorrhagic stroke, ICH, the activity of NOX2 increased significantly in the striatum after ICH [103]. Increased expression of gp91phox (NOX2) was mainly observed in activated microglia in ICH-injured brains [106].

These findings indicated that NOX activation has influences the early stage of hemorrhagic stroke and the relatively prolonged stage of ischemic stroke [40].

Table 1. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) expressions in three major types of stroke.

| Stroke Types          | Ischemic Stroke | Subarachnoid Hemorrhage | Intracerebral Hemorrhage |
|-----------------------|-----------------|-------------------------|--------------------------|
| Region Cell types     | Cortex, hippocampus, cerebral arteries Neurons, astrocytes, microglia | Cortex, striatum neurons, astrocytes | Striatum Microglia |
| NOX isoforms          | NOX1, NOX2, NOX4 | NOX2, NOX4               | NOX2                     |

5. Association of NADPH Oxidase in Cognitive Impairment

We focused on the involvement of the NOXs in the cognitive deficits of vascular and non-vascular diseases in this section. Emerging evidence demonstrates that NOX oxidases are involved in the cognitive dysfunction observed in various diseases and in vivo experiments (Table 2).

In cerebrovascular damaged models such as chronic hypoperfusion [18,97–99], cerebral ischemic reperfusion [107], and intermittent hypoxia [108–111] NOX activity and expression of NOX isoforms (NOX1, NOX2, p67phox, and p47phox) increased and cognitive functions were impaired. However, treatment of NOX inhibitor apocynin, ROS scavenger tempol, Rac GTPase inhibitor, downregulation
of NOX1 mRNA, and gp91phox knockout reversed those impaired cognitive behaviors. Moreover, aged AD-related transgenic mice have increased NOX activities and expressions of NOX2 and NOX4 correlated with cognitive decline. Their mechanisms may involve oxidative stress and deposition of amyloid beta [112–115].

Furthermore, studies on cognitive deficits in non-vascular disease demonstrated that increased NOX2 and p47phox expression and activation was involved in cognitive impairment in traumatic brain injury (TBI) [116–119], various encephalopathies [120–123], and metabolic diseases [13,124,125]. Chandran et al. [116] reported that NOX2 increased and transcription factor Nrf2 that decreased ROS were induced after TBI. The combination therapy (NOX inhibitor apocynin + Nrf2 activator TBHQ) improved cognitive dysfunction in TBI [116]. Di Filippo et al., found that multiple-sclerosis-associated cognitive dysfunction was caused by synaptic dysfunction via a long-term potentiation (LTP) blockade mediated by NOX2 [120]. Ji et al. and Hernandes et al. showed that selective phenotype loss of interneurons mediated by NOX2 activation lead to cognitive impairments in a mouse model of sepsis-associated encephalopathy (SAE) [122,123]. Won et al. [124] confirmed the relationship between cognitive deficits and recurrent hypoglycemia in diabetic rats. They found that NOX-activity dependent oxidative damage and microglial activation increased in the dendritic region of hippocampal CA1 by hypoglycemia in diabetic rat. This study suggests that oxidative injury by hypoglycemia is linked to long term cognitive dysfunction in diabetic patients [124].

More interestingly, Ansari and Scheff showed that the overall NOX enzyme activity level and protein levels of p67phox, p47phox, and p40phox isoforms were elevated in the human postmortem brains of Alzheimer’s disease (AD) [126]. Another human study by Bruce-Keller at al. found significant elevations in NOX activity and gp91phox and p47phox expression in the temporal gyri of mild cognitive impairment (MCI) patients when compared with the controls [127]. The increased gp91phox and p47phox expression were shown in the microglia and neurons [127]. Human studies have suggested that an elevated NOX-associated redox pathway might contribute to AD progression [126,127].

Table 2. Experiments of NOX expressions associated cognitive function.

| Disease model                                      | Increase NOX isoforms | Control of NOX | Mechanism of action                                      | Reference |
|---------------------------------------------------|-----------------------|----------------|----------------------------------------------------------|-----------|
| Two-vessel occlusion rat                           | gp91phox, p47phox, or p67phox | Apocynin 1 | Oxidative stress                                         | [98]      |
|                                                   | NOXs activity, NOX1   | Apocynin, shRNA NOX1 AAV | Oxidative stress                                         | [18]      |
| bilateral common carotid artery stenosis mice     | NOXs activity         | Apocynin      | Oxidative stress                                         | [107]     |
|                                                   | p67phox               | Tempol 2      | Oxidative stress                                         | [99]      |
| cerebral ischemic reperfusion rat                 | NOXs activity         | Rac GTPase inhibitor (NSC23766) | Oxidative stress                                         | [97]      |
| Obstructive sleep apnea, Long-term exposure to intermittent hypoxia (LTHI) mice | NOX2 (gp91phox), p47phox, p22phox | gp91phox(-/-), erythropoietin, Apocynin | Lipid peroxidation and oxidative DNA damage | [108–111] |
| Aged Tg2576 Mice                                  | NOXs activity         | Apocynin      | Oxidative stress and cerebrovascular dysfunction          | [112]     |
| Aged APP and PS1 knock-in mice                    | NOXs activity, NOX4   | Young age     | Deposition of Aβ1-42                                      | [113]     |
| Tg2576 and NOX2(-/-) mice                         | NOX2                  | NOX peptide Inhibitor gp91ds-tat NOX2(-/-) | ROS generation                                           | [114]     |
| gp91phox(-/-) and IL-6(-/-) aged mice             | NOX2                  | Apocynin, gp91phox(-/-), IL-6(-/-) | Oxidative stress                                         | [115]     |
| ACE2KO mice                                       | p22phox, p40phox, p67phox, and gp91phox | angiotensin (Ang)-converting enzyme (ACE), Tempol | Oxidative stress                                         | [128]     |
Table 2. Cont.

| Disease model                              | Increase NOX isoforms | Control of NOX | Mechanism of action | Reference |
|--------------------------------------------|-----------------------|----------------|---------------------|-----------|
| Renin/angiotensinogen transgenic mice      | p47phox and Nox4      | Tempol         | Oxidative stress    | [129]     |
| TBI                                        | NOX2                  | Apocynin, NOX2(-/-) | ROS formation       | [116]     |
| Moderate lateral fluid percussion injury   | NOXs activity         | bradykinin receptors B2 antagonist (HOE-140), Apocynin | ROS formation | [117,118] |
| Post-traumatic stress disorder             | NOX2                  | Environmental enrichment | Oxidative stress | [119]     |
| Eencephalomyelitis model of multiple sclerosis | NOX2                  | Minocycline 3, apocynin | Hippocampal synaptic plasticity deficit | [120]     |
| Sepsis-associated encephalopathy           | NOX2                  | Apocynin, gp91phox(-/-) | Inflammation and oxidative stress | [122,123] |
| Minimal hepatic encephalopathy rats        | p47phox               | Apocynin       | ROS formation       | [121]     |
| Recurrent/moderate hypoglycemia rat         | NOXs activity         | Apocynin       | Oxidative damage    | [124]     |
| Streptozotocin diabetes induced vascular dementia in rats | NOXs activity | NOX inhibitor, 4′-hydroxy-3′-methoxyacetophenone | Oxidative stress | [130]     |
| Endoplasmic reticulum stress, domoic acid-treated mice | p47phox and gp91phox | estrogen receptor-α | ROS formation, ER stress | [131]     |
| Sleep fragmentation in mice                | gp91phox              | gp91phox(-/-) mice | Lipid peroxidation and oxidative DNA damage | [132]     |
| Postoperative aging mice                   | NOX2                  | Apocynin       | Oxidative stress    | [133,134] |
| Ketamine treated rats                      | NOX2                  | Apocynin       | Oxidative damage    | [135]     |
| Sevoflurane exposure mice                  | p22 phox              | Apocynin       | Increasing superoxide concentrations | [136]     |
| Chronic granulomatous disease mice         | gp91phox and p47phox  | diphenylene iodonium or apocynin gp91phox and p47phox KO | LTP Blocking | [137]     |
| p47phox and nNOS double KO mice            | p47phox               | p47phox(-/-) and nNOS(-/-) | ROS and NO formation | [138]     |
| AD postmortem brains                       | p67phox, p47phox, and p47phox | Increasing of redox pathways | | [126]     |
| MCI postmortem brains                      | NOXs activity, gp91phox, p47phox | Microglia activation | | [127]     |

1 NOX inhibitor, Apocynin; 2 ROS scavengers, Tempol; 3 Minocycline, antibiotic. MCI: mild cognitive impairment; KO: knockout; ACE: angiotensin (Ang)-converting enzyme.

6. Conclusions

VaD can result from a loss of brain cells induced by hypoperfusion via damage to the vascular system. The factors that can cause vascular damage in VaD include aging, hypertension, and stroke. NOX oxidases play a role as a major ROS generator in cerebrovascular and neurodegenerative diseases. NOX-mediated ROS induce neuroinflammation and OS in blood vessels in conditions of aging, hypertension, and stroke. Moreover, NOX activation has also been linked to cognitive impairment in various neurological disorders. In this review, we summarized the current research regarding the association between risk factors for VaD and NOX: (1) Increased NOX expression was associated with the aging risk factor; (2) NOX activation produced intracellular H2O2, which induced vascular hypertrophy as a hypertension risk factor; (3) Increased activation of the NOX1, NOX2, and NOX4 isoforms was involved in ROS production and the development of the pathological condition in stroke risk factor; and (4) NOXs associated cognitive impairment was involved not only in vascular dementia but also in non-vascular diseases.
Considering the relationship between NOX and the risk factors for VaD (including aging, hypertension, and stroke), we suggest that further studies are necessary to examine the different roles of the vascular NOX isoforms and neuronal NOX isoforms in VaD. Moreover, we emphasize the contention that the regulation of NOX levels in cerebral vessels and the modulation of NOX activation in neurons and glial cells are important for the prevention and treatment of VaD.

Therefore, regulation of NOX may serve as a potential therapeutic target for VaD. Furthermore, emerging translational studies for controlling the risk factors through NOX regulation in VaD may have serious impacts on the significance of clinical application.

**Acknowledgments:** This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Information and Communications Technology (ICT) and Future Planning (NRF-2014R1A2A1A11050236 grant to DHC, NRF-2014R1A2A1A11050248 and NRF-2017R1A2B4004837 grant to JL); a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C2339); and the National Research Foundation of Korea (NRF) grant funded by the Korean government (NRF-2016R1A5A2012284).

**Author Contributions:** Dong-Hee Choi and Jongmin Lee conceived this review and drafted the manuscript. Dong-Hee Choi projected and designed the schematic picture. All authors reviewed and approved the submitted manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| NADPH        | Nicotinamide adenine dinucleotide phosphate |
| OS           | Oxidative stress |
| VaD          | Vascular dementia |
| ROS          | Reactive oxygen species |
| NOX          | NADPH oxidase |
| phox         | Phagocytic oxidase |
| DUOX         | Dual oxidase |
| NOXO1        | NOX organizer 1 |
| NOXA1        | NOX activator 1 |
| Rac          | Ras-related C3 botulinum toxin substrate |
| Ang II       | Angiotensin II |
| SAH          | Subarachnoid hemorrhage |
| ICH          | Intracerebral hemorrhage |
| CA1          | Cornu Ammonis 1 |
| ACE          | Angiotensin (Ang)-converting enzyme |
| IL-6         | Interleukin-6 |
| nNOS         | Neuronal nitric oxide synthase |
| TBI          | Traumatic brain injury |
| TBHQ         | Tertiary Butylhydroquinone |
| LTP          | Long-term potentiation |
| SAE          | Sepsis-associated encephalopathy |
| AD           | Alzheimer’s disease |
| KO           | Knockout |
| Nrf2         | NF-E2-related factor-2 |
References

1. McGuinness, B.; Craig, D.; Bullock, R.; Passmore, P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. 2016, 1, CD003160.
2. Gorelick, P.B.; Scuteri, A.; Black, S.E.; Decarli, C.; Greenberg, S.M.; Iadecola, C.; Launer, L.J.; Laurent, S.; Lopez, O.L.; Nyenhuis, D.; et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011, 42, 2672–2713. [CrossRef] [PubMed]
3. Appleton, J.P.; Scutt, P.; Sprigg, N.; Bath, P.M. Hypercholesterolaemia and vascular dementia. Clin. Sci. 2017, 131, 1561–1578. [CrossRef] [PubMed]
4. Van Oijen, M.; de Jong, F.J.; Witteman, J.C.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M. Atherosclerosis and risk for dementia. Ann. Neurol. 2007, 61, 403–410. [CrossRef] [PubMed]
5. Song, J.; Lee, W.T.; Park, K.A.; Lee, J.E. Association between risk factors for vascular dementia and apolipoprotein. Biomed. Res. Int. 2014, 2014, 261672. [CrossRef] [PubMed]
6. Venkat, P.; Chopp, M.; Chen, J. Models and mechanisms of vascular dementia. Exp. Neurol. 2015, 272, 97–108. [CrossRef] [PubMed]
7. Craft, S. The role of metabolic disorders in alzheimer disease and vascular dementia: Two roads converged. Arch. Neurol. 2009, 66, 300–305. [CrossRef] [PubMed]
8. Fillit, H.; Nash, D.T.; Rundek, T.; Zuckerman, A. Cardiovascular risk factors and dementia. Ann. J. Geriatr. Pharmacother. 2008, 6, 100–118. [CrossRef] [PubMed]
9. Honjo, K.; Black, S.E.; Verheoff, N.P. Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade. Can. J. Neurol. Sci. 2012, 39, 712–728. [CrossRef] [PubMed]
10. Purnell, C.; Gao, S.; Callahan, C.M.; Hendrie, H.C. Cardiovascular risk factors and incident alzheimer disease: A systematic review of the literature. Alzheimer Dis. Assoc. Disord. 2009, 23, 1–10. [CrossRef] [PubMed]
11. Singh, U.; Jialal, I. Oxidative stress and atherosclerosis. Pathophysiology 2006, 13, 129–142. [CrossRef] [PubMed]
12. Li, H.; Horke, S.; Forstermann, U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014, 237, 208–219. [CrossRef] [PubMed]
13. Liu, H.; Zhang, J. Cerebral hypoperfusion and cognitive impairment: The pathogenic role of vascular oxidative stress. Int. J. Neurosci. 2012, 122, 494–499. [CrossRef] [PubMed]
14. Zhang, X.; Wu, B.; Nie, K.; Jia, Y.; Yu, J. Effects of acupuncture on declined cerebral blood flow, impaired mitochondrial respiratory function and oxidative stress in multi-infarct dementia rats. Neurochem. Int. 2014, 65, 23–29. [CrossRef] [PubMed]
15. Drummond, G.R.; Seladnis, S.; Griendling, K.K.; Sobey, C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug. Discov. 2011, 10, 453–471. [CrossRef] [PubMed]
16. Luca, M.; Luca, A.; Calandra, C. The role of oxidative damage in the pathogenesis and progression of alzheimer’s disease and vascular dementia. Oxid. Med. Cell. Longev. 2015, 2015, 504678. [CrossRef] [PubMed]
17. Zekry, D.; Epperson, T.K.; Krause, K.H. A role for nox nadh oxidases in alzheimer’s disease and other types of dementia? IUBMB Life 2003, 55, 307–313. [CrossRef] [PubMed]
18. Choi, D.H.; Lee, K.H.; Kim, J.H.; Seo, J.H.; Kim, H.Y.; Shin, C.Y.; Han, J.S.; Han, S.H.; Kim, Y.S.; Lee, J. N'Dph oxidase 1, a novel molecular source of ROS in hippocampal neuronal death in vascular dementia. Antioxid. Redox. Signal. 2014, 21, 533–550. [CrossRef] [PubMed]
19. Kim, H.A.; Miller, A.A.; Drummond, G.R.; Thrift, A.G.; Arumugam, T.V.; Phan, T.G.; Srikanth, V.K.; Sobey, C.G. Vascular cognitive impairment and alzheimer’s disease: Role of cerebral hypoperfusion and oxidative stress. N-S Arch. Pharmacol. 2012, 385, 953–959. [CrossRef] [PubMed]
20. O’Brien, J.T.; Thomas, A. Vascular dementia. Lancet 2015, 386, 1698–1706. [CrossRef]
21. Cervellati, C.; Romani, A.; Seripa, D.; Cremonini, E.; Bösi, C.; Magon, S.; Passaro, A.; Bergamini, C.M.; Pilotto, A.; Zuliani, G. Oxidative balance, homocysteine, and uric acid levels in older patients with late onset alzheimer’s disease or vascular dementia. J. Neurol. Sci. 2014, 337, 156–161. [CrossRef] [PubMed]
22. Yang, J.; Wong, A.; Wang, Z.; Liu, W.; Au, L.; Xiong, Y.; Chu, W.W.; Leung, E.Y.; Chen, S.; Lau, C.; et al. Risk factors for incident dementia after stroke and transient ischemic attack. Alzheimer’s Dement. 2015, 11, 16–23. [CrossRef] [PubMed]
23. Wiesmann, M.; Kiliaan, A.J.; Claassen, J.A. Vascular aspects of cognitive impairment and dementia. *J. Cereb. Blood Flow Metab.* **2013**, *33*, 1696–1706. [CrossRef] [PubMed]

24. Bennett, S.; Grant, M.M.; Aldred, S. Oxidative stress in vascular dementia and alzheimer’s disease: A common pathology. *J. Alzheimers Dis.* **2009**, *17*, 245–257. [CrossRef] [PubMed]

25. Polidori, M.C.; Mattioli, P.; Aldred, S.; Cecchetti, R.; Stahl, W.; Griffiths, H.; Senin, U.; Sies, H.; Mecocci, P. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: Relevance to alzheimer disease and vascular dementia. *Dement. Geriatr. Cogn. Disord.* **2004**, *18*, 265–270. [CrossRef] [PubMed]

26. Casado, A.; Encarnacion Lopez-Fernandez, M.; Concepcion Casado, M.; de La Torre, R. Lipid peroxidation and antioxidant enzyme activities in vascular and alzheimer dementias. *Neurochem. Res.* **2008**, *33*, 450–458. [CrossRef] [PubMed]

27. Gustaw-Rothenberg, K.; Kowalczuk, K.; Stryjecka-Zimmer, M. Lipids’ peroxidation markers in alzheimer’s disease and vascular dementia. *Geriatr. Gerontol. Int.* **2010**, *10*, 161–166. [CrossRef] [PubMed]

28. Gackowski, D.; Rozalski, R.; Siomek, A.; Dziaman, T.; Nicpon, K.; Klimarczyk, M.; Araszkiewicz, A.; Olinski, R. Oxidative stress and oxidative DNA damage is characteristic for mixed alzheimer disease/vascular dementia. *J. Neurol. Sci.* **2008**, *266*, 57–62. [CrossRef] [PubMed]

29. Maritim, A.C.; Sanders, R.A.; Watkins, J.B., 3rd. Diabetes, oxidative stress, and antioxidants: A review. *J. Biochem. Mol. Toxicol.* **2003**, *17*, 24–38. [CrossRef] [PubMed]

30. Dias, I.H.; Polidori, M.C.; Griffiths, H.R. Hypercholesterolaemia-induced oxidative stress at the blood-brain barrier. *Biochem. Soc. Trans.* **2014**, *42*, 1001–1005. [CrossRef] [PubMed]

31. Rubattu, S.; Pagliaro, B.; Piereilli, G.; Santolamazza, C.; Castro, S.D.; Mennuni, S.; Volpe, M. Pathogenesis of target organ damage in hypertension: Role of mitochondrial oxidative stress. *Int. J. Mol. Sci.* **2014**, *16*, 823–839. [CrossRef] [PubMed]

32. Oliveira, H.C.; Cosso, R.G.; Alberici, L.C.; Maciel, E.N.; Salerno, A.G.; Dorighello, G.G.; Velho, J.A.; de Faria, E.C.; Vercesi, A.E. Oxidative stress in atherosclerosis-prone mouse is due to low antioxidant capacity of mitochondria. *FASEB J.* **2005**, *19*, 278–280. [CrossRef] [PubMed]

33. Luc, G.; Fruchart, J.C. Oxidation of lipoproteins and atherosclerosis. *Am. J. Clin. Nutr.* **1991**, *53*, 2065–2095. [PubMed]

34. Polidori, M.C.; Frei, B.; Cherubini, A.; Nelles, G.; Rordorf, G.; Keaney, J.F., Jr.; Schwamm, L.; Mecocci, P.; Koroshetz, W.J.; Beal, M.F. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. *Free Radic. Biol. Med.* **1998**, *25*, 561–567. [CrossRef]

35. Bedard, K.; Krause, K.H. The NOX family of ROS-generating nadph oxidases: Physiology and pathophysiology. *Physiol. Rev.* **2007**, *87*, 245–313. [CrossRef] [PubMed]

36. Rossi, F.; Zatti, M. Biochemical aspects of phagocytosis in polymorphonuclear leucocytes. Nadh and nadph oxidation by the granules of resting and phagocytizing cells. *Experientia* **1964**, *20*, 21–23. [CrossRef] [PubMed]

37. Cheng, G.; Cao, Z.; Xu, X.; van Meir, E.G.; Lambeth, J.D. Homologs of gp91phox: Cloning and tissue expression of nox3, nox4, and nox5. *Gene* **2001**, *269*, 131–140. [CrossRef] [PubMed]

38. Geiszt, M.; Leto, T.L. The Nox family of NAD(P)H oxidases: Host defense and beyond. *J. Biol. Chem.* **2004**, *279*, 51715–51718. [CrossRef] [PubMed]

39. Pandyala, S.; Natarajan, V. Redox regulation of Nox proteins. *Respir. Physiol. Neurobiol.* **2010**, *174*, 265–271. [CrossRef] [PubMed]

40. Ma, M.W.; Wang, J.; Zhang, Q.; Wang, R.; Dhandapani, K.M.; Vadlamudi, R.K.; Brann, D.W. NADPH oxidase in brain injury and neurodegenerative disorders. *Mol. Neurodegener.* **2017**, *12*, 7. [CrossRef] [PubMed]

41. Dutta, S.; Rittinger, K. Regulation of NOXO1 activity through reversible interactions with p22 and NOXA1. *PLoS ONE* **2010**, *5*, e10478. [PubMed]

42. Leto, T.L.; Morand, S.; Hurt, D.; Ueyama, T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. *Antioxid. Redox. Signal.* **2009**, *11*, 2607–2619. [CrossRef] [PubMed]

43. Streeter, J.; Thiel, W.; Briege, K.; Miller, F.J., Jr. Opportunity Nox: The future of NADPH oxidases as therapeutic targets in cardiovascular disease. *Cardiovasc. Ther.* **2013**, *31*, 125–137. [CrossRef] [PubMed]

44. Nguyen Dinh Cat, A.; Montezano, A.C.; Burger, D.; Touyz, R.M. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. *Antioxid. Redox. Signal.* **2013**, *19*, 1110–1120. [CrossRef] [PubMed]

45. Gray, S.P.; Jandeleit-Dahm, K.A. The role of NADPH oxidase in vascular disease—Hypertension, atherosclerosis & stroke. *Curr. Pharm. Des.* **2015**, *21*, 5933–5944. [PubMed]
46. Miller, A.A.; Drummond, G.R.; Sobey, C.G. Novel isoforms of NADPH-oxidase in cerebral vascular control. *Pharmacol. Ther.* **2006**, *111*, 928–948. [CrossRef] [PubMed]

47. Paravicini, T.M.; Chrissobolis, S.; Drummond, G.R.; Sobey, C.G. Increased NADPH-oxidase activity and Nox4 expression during chronic hypertension is associated with enhanced cerebral vasodilatation to NADPH in vivo. *Stroke* **2004**, *35*, 584–589. [CrossRef] [PubMed]

48. Miller, A.A.; Drummond, G.R.; Schmidt, H.H.; Sobey, C.G. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. *Circ. Res.* **2005**, *97*, 1055–1062. [CrossRef] [PubMed]

49. Ago, T.; Kitaizono, T.; Kuroda, J.; Kumai, Y.; Kamouchi, M.; Ooboshi, H.; Wakasaka, M.; Kawahara, T.; Rokutan, K.; Ibayashi, S.; et al. NAD(P)H oxidases in rat basilar arterial endothelial cells. *Stroke* **2005**, *36*, 1040–1046. [CrossRef] [PubMed]

50. Kazama, K.; Anrather, J.; Zhou, P.; Girouard, H.; Frys, K.; Milner, T.A.; Iadecola, C. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. *Circ. Res.* **2004**, *95*, 1019–1026. [CrossRef] [PubMed]

51. Chrissobolis, S.; Faraci, F.M. The role of oxidative stress and NADPH oxidase in cerebrovascular disease. *Trends Mol. Med.* **2008**, *14*, 495–502. [CrossRef] [PubMed]

52. Erdos, B.; Snipes, J.A.; Tulbert, C.D.; Katakam, P.; Miller, A.W.; Busija, D.W. Rosuvastatin improves cerebral blood flow in cerebral small vessel disease. *Stroke* **2007**, *38*, 1815–1821. [CrossRef] [PubMed]

53. Matsumoto, T.; Kobayashi, T.; Wachi, H.; Seyama, Y.; Kamata, K. Vascular NAD(P)H oxidase mediates endothelial dysfunction in basilar arteries from Otsuka long-evans tokushima fatty (OLETF) rats. *Atherosclerosis* **2007**, *192*, 15–24. [CrossRef] [PubMed]

54. Mayhan, W.G.; Arrick, D.M.; Sharpe, G.M.; Patel, K.P.; Sun, H. Inhibition of NAD(P)H oxidase alleviates age-related alterations in reactivity of cerebral arterioles: Role of oxidative stress. *Microcirculation* **2008**, *15*, 225–236. [CrossRef] [PubMed]

55. Mayhan, W.G.; Arrick, D.M.; Sharpe, G.M.; Sun, H. Age-related alterations in reactivity of cerebral arterioles. *Microcirculation* **2008**, *15*, 225–236. [CrossRef] [PubMed]

56. Park, L.; Koizumi, K.; El Jamal, S.; Zhou, P.; Previti, M.L.; Van Nostrand, W.E.; Carlson, G.; Iadecola, C. Age-dependent neurovascular dysfunction and damage in a mouse model of cerebral amyloid angiopathy. *Stroke* **2014**, *45*, 1815–1821. [CrossRef] [PubMed]

57. Park, L.; Anrather, J.; Girouard, H.; Zhou, P.; Iadecola, C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. *J. Cereb. Blood Flow. Metab.* **2007**, *27*, 1908–1918. [CrossRef] [PubMed]
65. Rajagopalan, S.; Kurz, S.; Munzel, T.; Tarpey, M.; Freeman, B.A.; Griendling, K.K.; Harrison, D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J. Clin. Investig.* 1996, 97, 1916–1923. [CrossRef] [PubMed]

66. Ding, L.; Chapman, A.; Boyd, R.; Wang, H.D. ERK activation contributes to regulation of spontaneous contractile tone via superoxide anion in isolated rat aorta of angiotensin II-induced hypertension. *Am. J. Physiol. Heart Circ. Physiol.* 2007, 292, H2997–3005. [CrossRef] [PubMed]

67. Nakane, H.; Miller, F.J., Jr.; Faraci, F.M.; Toyoda, K.; Heistad, D.D. Gene transfer of endothelial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction. *Hypertension* 2000, 35, 595–601. [CrossRef] [PubMed]

68. Faraci, F.M.; Lamping, K.G.; Modrick, M.L.; Ryan, M.J.; Sigmund, C.D.; Didion, S.P. Cerebral vascular effects of angiotensin II: New insights from genetic models. *J. Cereb. Blood Flow. Metab.* 2006, 26, 449–455. [CrossRef] [PubMed]

69. Chu, Y.; Alwahdani, A.; Iida, S.; Lund, D.D.; Faraci, F.M.; Heistad, D.D. Vascular effects of the human extracellular superoxide dismutase R213G variant. *Circulation* 2005, 112, 1047–1053. [CrossRef] [PubMed]

70. Feldberg, W.; Myers, R.D.; Veale, W.L. Perfusion from cerebral ventricle to cisterna magna in the unanaesthetized cat. Effect of calcium on body temperature. *J. Physiol.* 1970, 207, 403–416. [CrossRef] [PubMed]

71. Chabrashvili, T.; Kitiyakara, C.; Blau, J.; Karber, A.; Aslam, S.; Welch, W.J.; Wilcox, C.S. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2003, 285, R117–124. [CrossRef] [PubMed]

72. Matsuura, K.; Yamada, H.; lwata, K.; Jin, D.; Katsuyama, M.; Matsuki, M.; Takai, S.; Yamanishi, K.; Miyazaki, M.; Matsubara, H.; et al. Nox1 is involved in angiotensin II-mediated hypertension: A study in Nox1-deficient mice. *Circulation* 2005, 112, 2677–2685. [CrossRef] [PubMed]

73. Chrobis, S.; Banfi, B.; Sobey, C.G.; Faraci, F.M. Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. *J. Appl. Physiol.* 2012, 113, 184–191. [CrossRef] [PubMed]

74. Griendling, K.K.; Minieri, C.A.; Ollerenshaw, J.D.; Alexander, R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ. Res.* 1994, 74, 1141–1148. [CrossRef] [PubMed]

75. Touyz, R.M.; Chen, X.; Tabet, F.; Yao, G.; He, G.; Quinn, M.T.; Pagano, P.J.; Schiffrin, E.L. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: Regulation by angiotensin II. *Circ. Res.* 2002, 90, 1205–1213. [CrossRef] [PubMed]

76. Ushio-Fukai, M.; Zafari, A.M.; Fukui, T.; Ishizaka, N.; Griendling, K.K. P22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. *J. Biol. Chem.* 1996, 271, 23317–23321. [CrossRef] [PubMed]

77. Guzik, T.J.; Sadowski, J.; Guzik, B.; Jopek, A.; Kapelak, B.; Przybylowski, P.; Wierzbicki, K.; Korbut, R.; Harrison, D.G.; Chrobis, S.; Schiffrin, E.L. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. *Arterioscler. Thromb. Vasc. Biol.* 2006, 26, 333–339. [CrossRef] [PubMed]

78. Zafari, A.M.; Ushio-Fukai, M.; Akers, M.; Yin, Q.; Shah, A.; Harrison, D.G.; Taylor, W.R.; Griendling, K.K. P22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. *J. Biol. Chem.* 1996, 271, 23317–23321. [CrossRef] [PubMed]

79. Konior, A.; Schramm, A.; Czesnikiewicz-Guzik, M.; Guzik, T.J. NADPH oxidases in vascular pathology. *Antioxid. Redox. Signal.* 2014, 20, 2794–2814. [CrossRef] [PubMed]

80. Girouard, H.; Park, L.; Anrather, J.; Zhou, P.; Iadecola, C. Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through Nox-2-derived radicals. *Arterioscler. Thromb. Vasc. Biol.* 2006, 26, 826–832. [CrossRef] [PubMed]

81. Iadecola, C.; Davisson, R.L. Hypertension and cerebrovascular dysfunction. *Cell Metab.* 2006, 9, 595–601. [CrossRef] [PubMed]

82. Didion, S.P.; Faraci, F.M. Angiotensin II produces superoxide-mediated impairment of endothelial function in cerebral arteries. *Stroke* 2003, 34, 2038–2042. [CrossRef] [PubMed]

83. Brandes, R.P.; Takac, I.; Schroder, K. No superoxide—No stress?: Nox4, the good NADPH oxidase! *Arterioscler. Thromb. Vasc. Biol.* 2011, 31, 1255–1257. [CrossRef] [PubMed]
84. Schroder, K.; Zhang, M.; Benkhoff, S.; Mieth, A.; Pliquett, R.; Kosowsk, J.; Kruse, C.; Luedike, P.; Michaelis, U.R.; Weissmann, N.; et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. *Circ. Res.* 2012, 110, 1217–1225. [CrossRef] [PubMed]

85. Kleinschnitz, C.; Grund, H.; Wingler, K.; Armitage, M.E.; Jones, E.; Mittal, M.; Barit, D.; Schwarz, T.; Geis, C.; Kraft, P.; et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. *PLoS Biol.* 2010, 8, e1000479. [CrossRef] [PubMed]

86. Zhang, L.; Wu, J.; Duan, X.; Tian, X.; Shen, H.; Sun, Q.; Chen, G. NADPH oxidase: A potential target for treatment of stroke. *Oxid. Med. Cell. Longev.* 2016, 2016, 5026984. [CrossRef] [PubMed]

87. Chen, H.; Yoshioka, H.; Kim, G.S.; Jung, J.E.; Okami, N.; Sakata, H.; Maier, C.M.; Narasimhan, P.; Goeders, C.E.; Chan, P.H. Oxidative stress in ischemic brain damage: Mechanisms of cell death and potential molecular targets for neuroprotection. *Antioxid. Redox. Signal.* 2011, 14, 1505–1517. [CrossRef] [PubMed]

88. Chan, P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. *J. Cereb. Blood Flow. Metab.* 2001, 21, 2–14. [CrossRef] [PubMed]

89. Zhang, Q.G.; Laird, M.D.; Han, D.; Nguyen, K.; Scott, E.; Dong, Y.; Dhandapani, K.M.; Brann, D.W. Critical role of NADPH oxidase in neuronal oxidative damage and microglia activation following traumatic brain injury. *PLoS One* 2012, 7, e34504. [CrossRef] [PubMed]

90. Zhang, Q.G.; Raz, L.; Wang, R.; Han, D.; De Sevilla, L.; Yang, F.; Vadlamudi, R.K.; Brann, D.W. Estrogen attenuates ischemic oxidative damage via an ERα-mediated inhibition of NADPH oxidase activation. *J. Neurosci.* 2009, 29, 13823–13836. [CrossRef] [PubMed]

91. Zhang, Q.G.; Laird, M.D.; Han, D.; Nguyen, K.; Scott, E.; Dong, Y.; Dhandapani, K.M.; Brann, D.W. Critical role of NADPH oxidase in neuronal oxidative damage and microglia activation following traumatic brain injury. *PLoS One* 2012, 7, e34504. [CrossRef] [PubMed]

92. Choi, D.H.; Kim, J.H.; Lee, K.H.; Kim, H.Y.; Kim, Y.; Choi, W.S.; Lee, J. Role of neuronal NADPH oxidase 1 in the peri-infarct regions after stroke. *PLoS One* 2013, 10, e116814. [CrossRef] [PubMed]

93. Yoshioka, H.; Niizuma, K.; Katsu, M.; Okami, N.; Sakata, H.; Kim, G.S.; Narasimhan, P.; Chen, P.H. NADPH oxidase mediates striatal neuronal injury after transient global cerebral ischemia. *J. Cereb. Blood Flow. Metab.* 2011, 31, 568–880. [CrossRef] [PubMed]

94. Liu, H.; Wei, X.; Kong, L.; Liu, X.; Cheng, L.; Yan, S.; Zhang, X.; Chen, L. Nod2 is involved in the inflammatory response after cerebral ischemia-reperfusion injury and triggers NADPH oxidase 2-derived reactive oxygen species. *Int. J. Biol. Sci.* 2015, 11, 525–535. [CrossRef] [PubMed]

95. De Silva, T.M.; Brait, V.H.; Drummond, G.R.; Sobey, C.G.; Miller, A.A. Nox2 oxidase activity accounts for the oxidative stress and vasomotor dysfunction in mouse cerebral arteries following ischemic stroke. *PLoS One* 2011, 6, e28393. [CrossRef] [PubMed]

96. Radermacher, K.A.; Wingler, K.; Langhauser, F.; Altenhofer, S.; Kleinschnitz, C.; Schmidt, H.H. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. *Antioxid. Redox. Signal.* 2013, 18, 1418–1427. [CrossRef] [PubMed]

97. Raz, L.; Zhang, Q.G.; Zhou, C.; Han, D.; Gulati, P.; Yang, L.C.; Yang, F.; Wang, R.M.; Brann, D.W. Role of Rac1 gtpase in NADPH oxidase activation and cognitive impairment following cerebral ischemia in the rat. *PLoS One* 2015, 10, e124606. [CrossRef] [PubMed]

98. Shi, G.X.; Wang, X.R.; Yan, C.Q.; He, T.; Yang, J.W.; Zeng, X.H.; Xu, Q.; Zhu, W.; Du, S.Q.; Liu, C.Z. Acupuncture elicits neuroprotective effect by inhibiting NADPH oxidase-mediated reactive oxygen species production in cerebral ischaemia. *Sci. Rep.* 2015, 5, 17981. [CrossRef] [PubMed]

99. Dong, Y.F.; Kataoka, K.; Toyama, K.; Sueta, D.; Koibuchi, N.; Yamamoto, E.; Yata, K.; Tomimoto, H.; Ogawa, H.; Kim-Mitsuyama, S. Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hyperperfusion. *Hypertension* 2011, 58, 635–642. [CrossRef] [PubMed]

100. Tsukuda, K.; Mogi, M.; Li, J.M.; Iwanami, J.; Min, L.J.; Sakata, A.; Fujita, T.; Iwai, M.; Horiiuchi, M. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. *Hypertension* 2007, 50, 1099–1105. [CrossRef] [PubMed]

101. Ostrowski, R.P.; Colohan, A.R.; Zhang, J.H. Neuroprotective effect of hyperbaric oxygen in a rat model of subarachnoid hemorrhage. *Acta Neurochir. Suppl.* 2006, 96, 188–193. [PubMed]

102. Ostrowski, R.P.; Tang, J.; Zhang, J.H. Hyperbaric oxygen suppresses NADPH oxidase in a rat subarachnoid hemorrhage model. *Stroke* 2006, 37, 1314–1318. [CrossRef] [PubMed]
103. Yang, B.; Wang, S.; Yu, S.; Chen, Y.; Li, L.; Zhang, H.; Zhao, Y. C1q/tumor necrosis factor-related protein 3 inhibits oxidative stress during intracerebral hemorrhage via PKA signaling. *Brain Res.* 2017, 1657, 176–184. [CrossRef] [PubMed]

104. Kim, D.E.; Suh, Y.S.; Lee, M.S.; Kim, K.Y.; Lee, J.H.; Lee, H.S.; Hong, K.W.; Kim, C.D. Vascular NAD(P)H oxidase triggers delayed cerebral vasospasm after subarachnoid hemorrhage in rats. *Stroke* 2002, 33, 2687–2691. [CrossRef] [PubMed]

105. Zhang, L.; Li, Z.; Feng, D.; Shen, H.; Tian, X.; Li, H.; Wang, Z.; Chen, G. Involvement of Nox2 and Nox4 NADPH oxidases in early brain injury after subarachnoid hemorrhage. *Free Radic. Res.* 2017, 51, 316–328. [CrossRef] [PubMed]

106. Feng, L.; Chen, Y.; Ding, R.; Fu, Z.; Yang, S.; Deng, X.; Zeng, J. P2X7R blockade prevents NLRP3 inflammasome activation and brain injury in a rat model of intracerebral hemorrhage: Involvement of peroxynitrite. *J. Neuroinflamm.* 2015, 12, 190. [CrossRef] [PubMed]

107. Toyama, K.; Koibuchi, N.; Uekawa, K.; Hasegawa, Y.; Kataoka, K.; Katayama, T.; Sueta, D.; Ma, M.J.; Nakagawa, T.; Yasuda, O.; et al. Apoptosis signal-regulating kinase 1 is a novel target molecule for cognitive impairment induced by chronic cerebral hypoperfusion. *Arterioscler. Thromb. Vasc. Biol.* 2014, 34, 616–625. [CrossRef] [PubMed]

108. Ferreira, A.P.; Rodrigues, F.S.; Della-Pace, I.D.; Mota, B.C.; Oliveira, S.M.; de Campos Velho Gewehr, C.; Bobinski, F.; de Oliveira, C.V.; Brum, J.S.; Oliveira, M.S.; et al. The effect of NADPH-oxidase inhibitor apocynin on cognitive impairment induced by moderate lateral fluid percussion injury in mice overexpressing the amyloid precursor protein. *Proc. Natl. Acad. Sci. USA* 2008, 105, 1347–1352. [CrossRef] [PubMed]
119. Sun, X.R.; Zhang, H.; Zhao, H.T.; Ji, M.H.; Li, H.H.; Wu, J.; Li, K.Y.; Yang, J.J. Amelioration of oxidative stress-induced phenotype loss of parvalbumin interneurons might contribute to the beneficial effects of environmental enrichment in a rat model of post-traumatic stress disorder. *Behav. Brain Res.* 2016, 312, 84–92. [CrossRef] [PubMed]

120. Di Filippo, M.; de Iure, A.; Giampa, C.; Chiasserini, D.; Tozzi, A.; Orvietani, P.L.; Ghigliieri, V.; Tantucci, M.; Durante, V.; Quiroga-Varela, A.; et al. Persistent activation of microglia and NADPH drive hippocampal dysfunction in experimental multiple sclerosis. *Sci. Rep.* 2016, 6, 20926. [CrossRef] [PubMed]

121. Ding, S.; Yang, J.; Liu, L.; Ye, Y.; Wang, X.; Hu, J.; Chen, B.; Zhuge, Q. Elevated dopamine induces minimal hepatic encephalopathy by activation of astrocytic nadph oxidase and astrocytic protein tyrosine nitration. *Int. J. Biochem. Cell. Biol.* 2014, 55, 252–263. [CrossRef] [PubMed]

122. Ji, M.H.; Qiu, L.L.; Tang, H.; Ju, L.S.; Sun, X.R.; Zhang, H.; Jia, M.; Zuo, Z.Y.; Shen, J.C.; Yang, J.J. Sepsis-induced selective parvalbumin interneuron phenotype loss and cognitive impairments may be mediated by NADPH oxidase 2 activation in mice. *J. Neuroinflamm.* 2015, 12, 182. [CrossRef] [PubMed]

123. Hernandez, M.S.; D’Avila, J.C.; Trevelin, S.C.; Reis, P.A.; Kinjo, E.R.; Lopes, L.R.; Castro-Faria-Neto, H.C.; Cunha, F.Q.; Britto, L.R.; Bozza, F.A. The role of Nox2-derived ros in the development of cognitive impairment after sepsis. *J. Neuroinflamm.* 2014, 11, 36. [CrossRef] [PubMed]

124. Ansari, M.A.; Scheff, S.W. NADPH-oxidase activation and cognition in alzheimer disease progression. *Free Radic. Biol. Med.* 2011, 51, 171–178. [CrossRef] [PubMed]

125. Sharma, B.; Singh, N. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, convalesce behavior and biochemistry of hypertension induced vascular dementia in rats. *Pharmacol. Biochem. Behav.* 2013, 103, 821–830. [CrossRef] [PubMed]

126. Bruce-Keller, A.J.; Gupta, S.; Parrino, T.E.; Knight, A.G.; Ebenezer, P.J.; Weidner, A.M.; LeVine, H.; Keller, J.N.; Markesbery, W.R. NOX activity is increased in mild cognitive impairment. *Antioxid. Redox. Signal.* 2010, 12, 1371–1382. [CrossRef] [PubMed]

127. Lu, J.; Wu, D.M.; Zheng, Y.L.; Hu, B.; Cheng, W.; Zhang, Z.F. Purple sweet potato color attenuates domoic acid-induced cognitive deficits by promoting estrogen receptor-α-mediated mitochondrial biogenesis signaling in mice. *Free Radic. Biol. Med.* 2012, 52, 646–659. [CrossRef] [PubMed]

128. Nair, D.; Zhang, S.X.; Ramesh, V.; Hakim, F.; Kaushal, N.; Wang, Y.; Gozal, D. Sleep fragmentation induces cognitive impairments after repeated neonatal ketamine exposures. *Neurotox. Res.* 2016, 30, 593–605. [CrossRef] [PubMed]
136. Sun, Z.; Satomoto, M.; Adachi, Y.U.; Kinoshita, H.; Makita, K. Inhibiting nadph oxidase protects against long-term memory impairment induced by neonatal sevoflurane exposure in mice. *Br. J. Anaesth.* 2016, *117*, 80–86. [CrossRef] [PubMed]

137. Kishida, K.T.; Hoeffer, C.A.; Hu, D.; Pao, M.; Holland, S.M.; Klann, E. Synaptic plasticity deficits and mild memory impairments in mouse models of chronic granulomatous disease. *Mol. Cell. Biol.* 2006, *26*, 5908–5920. [CrossRef] [PubMed]

138. Walton, J.C.; Selvakumar, B.; Weil, Z.M.; Snyder, S.H.; Nelson, R.J. Neuronal nitric oxide synthase and NADPH oxidase interact to affect cognitive, affective, and social behaviors in mice. *Behav. Brain Res.* 2013, *256*, 320–327. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).